Danaher Corporation $DHR Shares Newly Purchased by Navigate Wealth Management LLC

Navigate Wealth Management LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 11,507 shares of the conglomerate’s stock, valued at approximately $2,549,000. Danaher makes up about 1.5% of Navigate Wealth Management LLC’s portfolio, making the stock its 16th biggest position.

Other institutional investors have also recently bought and sold shares of the company. Veery Capital LLC boosted its stake in shares of Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares in the last quarter. Studio Investment Management LLC grew its holdings in shares of Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after purchasing an additional 51 shares during the last quarter. JDH Wealth Management LLC increased its position in Danaher by 4.5% during the 1st quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after purchasing an additional 55 shares in the last quarter. OLD Second National Bank of Aurora increased its position in Danaher by 0.5% during the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after purchasing an additional 57 shares in the last quarter. Finally, Adelphi Trust Co increased its position in Danaher by 2.5% during the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. Guggenheim increased their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Royal Bank Of Canada boosted their target price on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Wells Fargo & Company lowered their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Finally, The Goldman Sachs Group increased their price target on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Trading Up 0.7%

Shares of NYSE:DHR traded up $1.63 during midday trading on Wednesday, hitting $224.47. 1,984,723 shares of the stock were exchanged, compared to its average volume of 4,449,140. The business’s 50-day moving average price is $212.41 and its 200 day moving average price is $195.13. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market capitalization of $157.80 billion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 2.78 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business earned $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. Analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.